Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma

Zhijian Duan, Danielle Chinn, Mei Juan Tu, Qian Yu Zhang, Jasmine Huynh, Justin Chen, Philip Mack, Aiming Yu, Edward Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The BCL-2 family of proteins, including anti-apoptotic members BCL-2, BCL-XL and MCL-1, are part of a complex network that controls apoptosis. BH3-mimetics such as ABT-263 inhibit anti-apoptotic BCL-2 proteins and have been developed as potential cancer therapeutics. Aurora Kinase A (AKA) is over-expressed in pancreatic cancer (PC) and controls G2-M transition during mitosis and AKA inhibitors have been developed that induce mitotic arrest. We hypothesized that mitotic arrest induced by AKA inhibition may sensitize PC to accelerated apoptosis by a BH3-mimetic. Our results demonstrated that ABT-263 plus MLN8237 treatment showed greater activity than either single drug alone, as well as strong synergism, in the inhibition of growth of pancreatic cell lines (AsPC-1, PANC-1, MIA PaCa-2, HPAF-II) and PC patient-derived organoids (PDOs). The higher efficacy of combination treatment was attributable to the higher levels of induction of apoptosis and reduction of MCL-1 in PC cells and PDOs. In addition, combination therapy was more effective than single drug in the suppression of tumor growth in AsPC-1 xenograft mouse models. Together, our findings suggest that combination therapy with ABT-263 and MLN8237 should be considered for further exploration as a novel treatment of deadly PC disease.

Original languageEnglish (US)
Pages (from-to)683-692
Number of pages10
JournalTranslational Oncology
Volume12
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Pancreatic Neoplasms
Aurora Kinase A
Adenocarcinoma
Apoptosis
Organoids
Therapeutics
Pancreatic Diseases
Apoptosis Regulatory Proteins
Growth
Mitosis
Heterografts
Pharmaceutical Preparations
Neoplasms
Cell Line
navitoclax
Proteins
MLN 8237

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma. / Duan, Zhijian; Chinn, Danielle; Tu, Mei Juan; Zhang, Qian Yu; Huynh, Jasmine; Chen, Justin; Mack, Philip; Yu, Aiming; Kim, Edward.

In: Translational Oncology, Vol. 12, No. 4, 01.04.2019, p. 683-692.

Research output: Contribution to journalArticle

Duan, Zhijian ; Chinn, Danielle ; Tu, Mei Juan ; Zhang, Qian Yu ; Huynh, Jasmine ; Chen, Justin ; Mack, Philip ; Yu, Aiming ; Kim, Edward. / Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma. In: Translational Oncology. 2019 ; Vol. 12, No. 4. pp. 683-692.
@article{882f984ec51840b6825903fc5aafa323,
title = "Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma",
abstract = "The BCL-2 family of proteins, including anti-apoptotic members BCL-2, BCL-XL and MCL-1, are part of a complex network that controls apoptosis. BH3-mimetics such as ABT-263 inhibit anti-apoptotic BCL-2 proteins and have been developed as potential cancer therapeutics. Aurora Kinase A (AKA) is over-expressed in pancreatic cancer (PC) and controls G2-M transition during mitosis and AKA inhibitors have been developed that induce mitotic arrest. We hypothesized that mitotic arrest induced by AKA inhibition may sensitize PC to accelerated apoptosis by a BH3-mimetic. Our results demonstrated that ABT-263 plus MLN8237 treatment showed greater activity than either single drug alone, as well as strong synergism, in the inhibition of growth of pancreatic cell lines (AsPC-1, PANC-1, MIA PaCa-2, HPAF-II) and PC patient-derived organoids (PDOs). The higher efficacy of combination treatment was attributable to the higher levels of induction of apoptosis and reduction of MCL-1 in PC cells and PDOs. In addition, combination therapy was more effective than single drug in the suppression of tumor growth in AsPC-1 xenograft mouse models. Together, our findings suggest that combination therapy with ABT-263 and MLN8237 should be considered for further exploration as a novel treatment of deadly PC disease.",
author = "Zhijian Duan and Danielle Chinn and Tu, {Mei Juan} and Zhang, {Qian Yu} and Jasmine Huynh and Justin Chen and Philip Mack and Aiming Yu and Edward Kim",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.tranon.2019.01.009",
language = "English (US)",
volume = "12",
pages = "683--692",
journal = "Translational Oncology",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "4",

}

TY - JOUR

T1 - Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma

AU - Duan, Zhijian

AU - Chinn, Danielle

AU - Tu, Mei Juan

AU - Zhang, Qian Yu

AU - Huynh, Jasmine

AU - Chen, Justin

AU - Mack, Philip

AU - Yu, Aiming

AU - Kim, Edward

PY - 2019/4/1

Y1 - 2019/4/1

N2 - The BCL-2 family of proteins, including anti-apoptotic members BCL-2, BCL-XL and MCL-1, are part of a complex network that controls apoptosis. BH3-mimetics such as ABT-263 inhibit anti-apoptotic BCL-2 proteins and have been developed as potential cancer therapeutics. Aurora Kinase A (AKA) is over-expressed in pancreatic cancer (PC) and controls G2-M transition during mitosis and AKA inhibitors have been developed that induce mitotic arrest. We hypothesized that mitotic arrest induced by AKA inhibition may sensitize PC to accelerated apoptosis by a BH3-mimetic. Our results demonstrated that ABT-263 plus MLN8237 treatment showed greater activity than either single drug alone, as well as strong synergism, in the inhibition of growth of pancreatic cell lines (AsPC-1, PANC-1, MIA PaCa-2, HPAF-II) and PC patient-derived organoids (PDOs). The higher efficacy of combination treatment was attributable to the higher levels of induction of apoptosis and reduction of MCL-1 in PC cells and PDOs. In addition, combination therapy was more effective than single drug in the suppression of tumor growth in AsPC-1 xenograft mouse models. Together, our findings suggest that combination therapy with ABT-263 and MLN8237 should be considered for further exploration as a novel treatment of deadly PC disease.

AB - The BCL-2 family of proteins, including anti-apoptotic members BCL-2, BCL-XL and MCL-1, are part of a complex network that controls apoptosis. BH3-mimetics such as ABT-263 inhibit anti-apoptotic BCL-2 proteins and have been developed as potential cancer therapeutics. Aurora Kinase A (AKA) is over-expressed in pancreatic cancer (PC) and controls G2-M transition during mitosis and AKA inhibitors have been developed that induce mitotic arrest. We hypothesized that mitotic arrest induced by AKA inhibition may sensitize PC to accelerated apoptosis by a BH3-mimetic. Our results demonstrated that ABT-263 plus MLN8237 treatment showed greater activity than either single drug alone, as well as strong synergism, in the inhibition of growth of pancreatic cell lines (AsPC-1, PANC-1, MIA PaCa-2, HPAF-II) and PC patient-derived organoids (PDOs). The higher efficacy of combination treatment was attributable to the higher levels of induction of apoptosis and reduction of MCL-1 in PC cells and PDOs. In addition, combination therapy was more effective than single drug in the suppression of tumor growth in AsPC-1 xenograft mouse models. Together, our findings suggest that combination therapy with ABT-263 and MLN8237 should be considered for further exploration as a novel treatment of deadly PC disease.

UR - http://www.scopus.com/inward/record.url?scp=85062421516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062421516&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2019.01.009

DO - 10.1016/j.tranon.2019.01.009

M3 - Article

AN - SCOPUS:85062421516

VL - 12

SP - 683

EP - 692

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

IS - 4

ER -